HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270007300954v1 47/7/806    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Karim, A. Articles by Laurent, A. Search for Related Content PubMed PubMed Citation Articles by Karim, A. Articles by Laurent, A. Social Bookmarking                         What's this?

Replicate Study Design in Bioequivalency Assessment, Pros and Cons: Bioavailabilities of the Antidiabetic Drugs Pioglitazone and Glimepiride Present in a Fixed-Dose Combination Formulation

From Takeda Global Research & Development Center, Inc, Deerfield, Illinois (Dr Karim, Ms Zhao, Ms Slater, Ms Bradford, Ms Schuster), and PPD Development, LP, Austin, Texas (Dr Laurent).

An open-label, randomized, 2-sequence, 4-period crossover (7-day washout period between treatment), replicate design study was conducted in 37 healthy subjects to assess intersubject and intrasubject variabilities in the peak (C_max) and total (AUC) exposures to 2 oral antidiabetic drugs, pioglitazone and glimepiride, after single doses of 30 mg pioglitazone and 4 mg glimepiride, given under fasted state, as commercial tablets coadministered or as a single fixed-dose combination tablet. Variabilities for AUC for coadministered and fixed-dose combination treatments were similar: 16% to 19% (intra) and 23% to 25% (inter) for pioglitazone and 18% to 19% (intra) and 29% to 30% for glimepiride (inter, excluding 1 poor metabolizer). Fixed-dose combination/coadministered least squares mean ratios of 0.86 and the 90% confidence intervals of these ratios for pioglitazone and glimepiride of between 0.80 and 1.25 for C_max, AUC_lqc, and AUC met the bioequivalency standards. Gender analysis showed that women showed mean of 16% and 30% higher exposure than men for glimepiride (excluding 1 poor metabolizer) and pioglitazone, respectively. There was considerable overlapping in the AUC values, making gender-dependent dosing unnecessary. Patients taking pioglitazone and glimepiride as cotherapy may replace their medication with a single fixed-dose combination tablet containing these 2 oral antidiabetic drugs.

Key Words: Fixed-dose combination • oral antidiabetics • pioglitazone • glimepiride • intersubject and intrasubject systemic exposure variability • bioequivalency • replicate study design

Address for correspondence: Aziz Karim, PhD, ABCP, FCP, Takeda Global Research & Development Center, Inc, One Takeda Parkway, Deerfield, IL 60015; e-mail: akarim{at}tgrd.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?